In Situ Caries of Fluoride Toothpastes
This study has been completed.
Sponsor:
GlaxoSmithKline
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00708123
First received: July 1, 2008
Last updated: NA
Last verified: July 2008
History: No changes posted
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | July 1, 2008 | ||||
Last Updated Date | July 1, 2008 | ||||
Start Date ICMJE | November 2007 | ||||
Primary Completion Date | |||||
Current Primary Outcome Measures ICMJE |
To use an in situ caries model to compare the retention phase of fluoride delivery from two test sodium fluoride toothpastes to a monofluorophosphate/ sodium fluoride toothpaste with respect to enamel remineralization potential. | ||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | No Changes Posted | ||||
Current Secondary Outcome Measures ICMJE |
Comparisons between treatments with respect to enamel remineralization potential. To compare the retention phase of fluoride delivery of all the study toothpastes to placebo and to each other with respect to enamel fluoride uptake. | ||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | In Situ Caries of Fluoride Toothpastes | ||||
Official Title ICMJE | Comparison of the Clinical Efficacy From the Retention Phase of Fluoride Delivery of Fluoride Toothpastes Using an in Situ Caries Model | ||||
Brief Summary | This study is to evaluate the effect of fluoride dentifrices on enamel with artificial caries lesions in an in situ model. |
||||
Detailed Description | |||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 3 | ||||
Study Design ICMJE | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double-Blind Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE | Drug: Fluoride | ||||
Study Arm (s) | |||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Enrollment ICMJE | 57 | ||||
Completion Date | |||||
Primary Completion Date | |||||
Eligibility Criteria ICMJE | Inclusion Criteria
Exclusion Criteria
|
||||
Gender | Both | ||||
Ages | 18 Years to 78 Years | ||||
Accepts Healthy Volunteers | Yes | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | United States | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00708123 | ||||
Other Study ID Numbers ICMJE | T3157503 | ||||
Has Data Monitoring Committee | |||||
Responsible Party | |||||
Study Sponsor ICMJE | GlaxoSmithKline | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | GlaxoSmithKline | ||||
Verification Date | July 2008 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |